Global Electric Off-Road Vehicle Market
Dublin, Sept. 23, 2022 (GLOBE NEWSWIRE) -- The "Flowable Hemostats Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Material, Product, Application, and End-user" report has been added to ResearchAndMarkets.com's offering. The flowable hemostats market is projected to reach US$ 458.9 million by 2028 from US$ 304.9 million in 2022. Increasing number of injuries and surgical procedures drives the overall market growth. Research and development (R&D) activities coupled with product innovations act as a future trend in the flowable hemostats market. The flowable hemostats market is segmented into Europe, China, and Japan. Injuries are a significant concern to public health in Europe. The BioMed Central Ltd. report states that across all European countries in 2019, 109.7 million people sustained injuries that required healthcare services, and around 458,669 people died from injuries. As a result, the number of surgical procedures is rising in Europe. The National Library of Medicine report states that about 10% of patients undergoing surgery in the UK have a high risk of complications accounting for 80% of postoperative deaths. The number of surgeries is increasing owing to rising musculoskeletal disorders associated with sports, age-related dysfunction, and occupational injuries. However, a sizeable proportion of health gains are lost owing to sports-related injuries. According to the BMJ Publishing Group Ltd. report, about 4.5 million people aged 15 years and above are treated annually for sports-associated injuries in the EU hospitals.
Moreover, the report also states that team ball sports account for almost 40% of hospital-treated sports injuries. Concussions are a major cause of mortality and morbidity. Concussions are considered the most diffuse brain injuries responsible for inducing mental status alterations. The National Library of Medicine report states that China has a large base of patients suffering from traumatic brain injury (TBI) compared to other countries, making this condition a major public health concern. Such factors are responsible for the high adoption of flowable hemostats, ultimately driving the market growth. The flowable hemostats market is segmented on the basis of material, product, application, and end user. Based on material, the flowable hemostats market is bifurcated into porcine gelatin and bovine gelatin. The bovine gelatin segment is estimated to hold a larger market share during 2022-2028.
Also, the same segment is likely to register a higher CAGR during the forecast period. Bovine gelatin is a protein-based product produced by partial hydrolysis of collagen. The collagen material is extracted from bovine tissue, such as bone and skin. The product has hemostatic properties and is used in admixture with thrombin to provide an excellent hemostat result. The increasing number of cardiovascular surgeries along with the geriatric population drives the flowable hemostat market growth for the bovine gelatin segment. Also, manufacturers are focusing on the manufacturing of innovative products.
For example, FloSeal, a product manufactured by Baxter Fremont, is composed of bovine gelatin matrix, calcium chloride, and human plasma thrombin. When this product is applied to superficial wounds or surgical sites, gelatin granules absorb blood and swell and produce a hemostat effect. Thus, aforementioned factors are driving the market for the bovine gelatin segment. Market Opportunities of Flowable Hemostats Market
There is an increase in the number of hospitals and surgical centers across the world. The hospitals & clinics segment accounts a considerable market share. Thus, there is a rising demand for surgical equipment, including medical devices and hemostat products, from newly established surgical centers and hospitals.
In October 2020, the Prime Minister of the UK announced plans to invest around US$ 4.3 billion in setting of 40 hospitals and a scheme for future funding for 48 hospitals by 2030. Also, in the past decade, India and China have witnessed significant improvements in healthcare infrastructure. The Commonwealth Fund report published in 2018 states that China has ~12,000 public and 21,000 private hospitals.
Moreover, according to the Statistics Bureau and Ministry of Internal Affairs and Communications report, as of October 2019, the number of hospitals in Japan accounted for 8,300, and the number of hospital beds was about 1,529,215 (1,212.1 per 100,000 people). In the fiscal year 2018, national medical care expenditure totaled US$ 0.32 trillion, 10.73% of Japan's national income. Therefore, the rising number of hospitals and clinics is expected to offer lucrative growth opportunities for the flowable hemostats market during the forecast period. The healthcare industry has been experiencing a rapid transformation in recent years. Various countries across the world have favored advanced technologies in healthcare. With the need for better healthcare facilities, Technology-Enabled Care (TEC) solutions are being referred to the healthcare systems, especially in the emerging economies.
A few primary factors, such as rising incidence of chronic illnesses and increasing aging population and pediatric care, boost the growth of the healthcare industry. With rising technical procedures, the utility of topical hemostats may help improve clinical outcomes. Thus, the ideal topical hemostats would offer reliable and prompt bleeding control. Therefore, the growth in the number of hospitals and surgical centers demands high adoption of flowable hemostat products, ultimately driving the overall flowable hemostats market growth. Key Topics Covered: 1. Introduction
2. Flowable Hemostats Market - Key Takeaways
4. Flowable Hemostats - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.2.1 Flowable Hemostats Market - Europe PEST Analysis 4.2.2 Flowable Hemostats Market - China and Japan PEST Analysis 4.3 Expert Opinion
5. Flowable Haemostats Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Increasing Injuries and Surgical Procedures 5.1.2 Rising Geriatric Population 5.2 Market Restraints 5.2.1 Poor Reimbursement Policies and Shortage of Skilled Professionals 5.3 Market Opportunities 5.3.1 Increasing Hospitals and Surgical Centres 5.4 Future Trends 5.4.1 Research and Development (R & amp;D) Activities Coupled With Product Innovation 5.5 Impact Analysis
6. Flowable Hemostats Market - Europe, China, and Japan Analysis 6.1 Flowable Hemostats Market Revenue Forecasts and Analysis 6.2 Flowable Hemostats Market - Market Potential Analysis, By Region 6.3 Company Analysis 6.3.1 Market Positioning of Key Players 6.3.2 Comparative Company Analysis 6.3.3 Growth Strategy Analysis 6.4 Performance of Key Players 6.4.1 Baxter 6.4.2 Ethicon
7. Flowable Hemostats Market Analysis - By Material 7.1 Overview 7.2 Flowable Hemostats Market Share, by Material, 2022 and 2028 (%) 7.3 Porcine Gelatin 7.3.1 Overview 7.3.2 Porcine Gelatin: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 7.4 Bovine Gelatin 7.4.1 Overview 7.4.2 Bovine Gelatin: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
8. Flowable Hemostats Market - By Product 8.1 Overview 8.2 Flowable Hemostats Market Share, by Product, 2022 and 2028 (%) 8.3 Active Haemostat 8.3.1 Overview 8.3.2 Active Haemostat: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 8.4 Passive Haemostat 8.4.1 Overview 8.4.2 Passive Haemostat: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 8.5 Combination Haemostat 8.5.1 Overview 8.5.2 Combination Haemostat: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
9. Flowable Hemostats Market - By Application 9.1 Overview 9.2 Flowable Hemostats Market Share, by Application, 2022 and 2028 (%) 9.3 General Surgery 9.3.1 Overview 9.3.2 General Surgery: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 9.4 Cardiac Surgery 9.4.1 Overview 9.4.2 Cardiac Surgery: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 9.5 Vascular Surgery 9.5.1 Overview 9.5.2 Vascular Surgery: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 9.6 Orthopedic Surgery 9.6.1 Overview 9.6.2 Orthopedic Surgery: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 9.7 Neuro and Spine Surgery 9.7.1 Overview 9.7.2 Neuro and Spine Surgery: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 9.8 Others 9.8.1 Overview 9.8.2 Others: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
10. Flowable Hemostats Market Analysis - By End User 10.1 Overview 10.2 Flowable Hemostats Market Share, by End User, 2022 and 2028, (%) 10.3 Hospitals and Clinics 10.3.1 Overview 10.3.2 Hospitals and Clinics: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 10.4 Ambulatory Surgery Centers 10.4.1 Overview 10.4.2 Ambulatory Surgery Centers: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million) 10.5 Others 10.5.1 Overview 10.5.2 Others: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
11. Flowable Hemostats Market Revenue and Forecast To 2028 - Country Analysis
12. Impact of COVID-19 Pandemic on Flowable Hemostats Market 12.1 Europe: Impact Assessment of COVID-19 Pandemic 12.2 China & Japan: Impact Assessment of COVID-19 Pandemic
13. Flowable Hemostats Market Industry Landscape 13.1 Overview 13.2 Growth Strategies in the Flowable Hemostats Market, 2022-2028 13.3 Inorganic Growth Strategies 13.3.1 Overview 13.4 Organic Growth Strategies 13.4.1 Overview
14. Company Profiles 14.1 Ethicon (Johnson & Johnson Services, Inc.) 14.1.1 Key Facts 14.1.2 Business Description 14.1.3 Products and Services 14.1.4 Financial Overview 14.1.5 SWOT Analysis 14.1.6 Key Developments 14.2 Baxter International Inc. 14.2.1 Key Facts 14.2.2 Business Description 14.2.3 Products and Services 14.2.4 Financial Overview 14.2.5 SWOT Analysis 14.2.6 Key Developments 14.3 Teleflex Incorporated 14.3.1 Key Facts 14.3.2 Business Description 14.3.3 Products and Services 14.3.4 Financial Overview 14.3.5 SWOT Analysis 14.3.6 Key Developments 14.4 Pfizer Inc. 14.4.1 Key Facts 14.4.2 Business Description 14.4.3 Products and Services 14.4.4 Financial Overview 14.4.5 SWOT Analysis 14.4.6 Key Developments 14.5 SYMATESE 14.5.1 Key Facts 14.5.2 Business Description 14.5.3 Products and Services 14.5.4 Financial Overview 14.5.5 SWOT Analysis 14.5.6 Key Developments 14.6 BD 14.6.1 Key Facts 14.6.2 Business Description 14.6.3 Products and Services 14.6.4 Financial Overview 14.6.5 SWOT Analysis 14.6.6 Key Developments 14.7 B. Braun Melsungen AG 14.7.1 Key Facts 14.7.2 Business Description 14.7.3 Products and Services 14.7.4 Financial Overview 14.7.5 SWOT Analysis 14.7.6 Key Developments
15. Europe & Asia Pacific Topical Hemostats Market Revenue and Forecast To 2028 - Country Analysis
For more information about this report visit https://www.researchandmarkets.com/r/um2229
Global Electric Off-Road Vehicle Market
On Wednesday, the Fed bumped up interest rates again, its third 75-basis point hike since June, and signaled that there could be two more such hikes by the end of this year. The conventional wisdom has the Fed acting properly, and aggressively, in an attempt to counter inflation raging at 40-year high levels. But conventional wisdom isn’t always right – and we can learn a lot by consulting the contrarians. Few top investors are more contrarian than Cathie Wood. The founder and manager of ARK Inv
KEY WORDS “I think we’re giving Powell too much praise. … The last two years are one of the biggest policy mistakes in the 110-year history of the Fed by staying so easy when everything was booming.
Homeowners beware. But don't panic, either.
You have just a few weeks to pounce on Treasury I bonds' sky-high interest rate. Also called Series I savings bonds, their interest rate is 9.62%.
And what it means for your wealth-building options.
The shipping company has developed a reputation as one of the best dividend stocks around
“We printed up too much money, and just thought the party would never end,” Icahn said, adding that with the Fed raising rates to fight inflation, "the party's over."
Novavax, Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $NVAX performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
Yahoo Finance Live anchor Seana Smith highlights stocks moving in after-hours trading, including Ford, FedEx, and Moderna.
As much as stocks are falling, moves in another financial market have even more profound implications for the global economy.
UBS's Colin Bristow raised his rating on the stock to Buy from Neutral, saying Well Street's expectations for sales of Mounjaro are too low.
Netflix Inc. is seeking a new chief accounting officer after its current one quit the role after less than four months.
Yahoo Finance's Jared Blikre joins the Live show to check out market and sector losses amid today's sell-off, while also looking at meme stocks and the travel industrial.
While it's undoubtedly challenging to choose between these two wireless titans, both have advantages and disadvantages.
Yes, there's a lot of economic concerns, but this is a buying opportunity (and things aren't nearly as bad as they seem).
Goldman finally decided to stop fighting the Fed and no longer sees the index finishing the year at 4300.
Boise, Idaho; Philadelphia; Pensacola, Fla.; Austin; and Reno, Nev.; Minnesota; and Utah are the housing markets with the most buyer pullback, says one home builder.
The market has soured on these stocks, but insiders are buying. Is it time to load up on these companies?
At a companywide all-hands meeting this week, Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) chief Sundar Pichai juggled tough questions from employees regarding cuts to travel and entertainment budgets, managing productivity, and potential layoffs. Employees questioned why Google is "nickel-and-diming employees" by cutting travel and swag budgets despite record profits and substantial cash reserves as it did after the pandemic. Pichai emphasized acting responsibly to tide through such critical sit
The S&P 500 could revisit its 52-week intraday low of 3636—or go even lower. But there could also be an "impulsive rally" that takes the index past 4100.